Guardant Health announces March 28, 2024 FDA panel review date for Shield colorectal cancer blood test

Guardant Health, Inc.

FDA's Molecular and Clinical Genetics Panel tentatively set to review Shield PMA on March 28, 2024, subject to confirmation.
Shield blood test data derived from ECLIPSE study of over 20,000 average-risk adults for colorectal cancer detection.
Co-CEO AmirAli Talasaz states proposed timing aligns with completing PMA process and launching Shield IVD in 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.